We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

91 hedge funds and large institutions have $214M invested in Concert Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

28% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 25

22% more capital invested

Capital invested by funds: $175M → $214M (+$38.7M)

15% more funds holding

Funds holding: 79 → 91 (+12)

Holders
91
Holders Change
+12
Holders Change %
+15.19%
% of All Funds
1.87%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
32
Reduced
25
Closed
10
Calls
$263K
Puts
–
Net Calls
+$263K
Net Calls Change
-$205K

Top Buyers

Rank Fund Capital Flow
1
SW
SVB Wealth
Massachusetts
+$3.66M
2
EP
Eversept Partners
New York
+$2.23M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.77M
4
Millennium Management
Millennium Management
New York
+$1.04M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$784K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$3M
2
ISL
Ingalls & Snyder LLC
New York
-$707K
3
Citadel Advisors
Citadel Advisors
Florida
-$692K
4
BCM
Bridgeway Capital Management
Texas
-$510K
5
N
Nuveen
North Carolina
-$415K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$21.4M – – –
Bank of America
2
Bank of America
North Carolina
$18.6M +$16.5K +1,717 +0.1%
RCM
3
RA Capital Management
Massachusetts
$18.5M – – –
BlackRock
4
BlackRock
New York
$18.1M +$668K +69,624 +4%
ISL
5
Ingalls & Snyder LLC
New York
$13.8M -$707K -73,764 -5%
Vanguard Group
6
Vanguard Group
Pennsylvania
$12.6M +$605K +63,042 +5%
Millennium Management
7
Millennium Management
New York
$12.1M +$1.04M +108,798 +10%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$11.1M -$54K -5,630 -0.5%
LC
9
L1 Capital
Australia
$9.63M +$9.29M +968,198 New
SFM
10
Sphera Funds Management
Israel
$6.97M -$3M -312,329 -31%
Renaissance Technologies
11
Renaissance Technologies
New York
$6.41M +$278K +29,000 +5%
Alyeska Investment Group
12
Alyeska Investment Group
Illinois
$5M +$488K +50,883 +11%
State Street
13
State Street
Massachusetts
$4.82M +$150K +15,689 +3%
Northern Trust
14
Northern Trust
Illinois
$4.11M +$752K +78,378 +23%
SW
15
SVB Wealth
Massachusetts
$3.79M +$3.66M +381,326 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$3.55M +$188K +19,633 +6%
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.5M -$120K -12,524 -3%
N
18
Nuveen
North Carolina
$3.38M -$415K -43,286 -11%
Prudential Financial
19
Prudential Financial
New Jersey
$3.06M -$168K -17,561 -5%
KCM
20
Kennedy Capital Management
Missouri
$2.63M +$34.5K +3,596 +1%
EP
21
Eversept Partners
New York
$2.32M +$2.23M +232,983 New
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$2.3M -$85.8K -8,947 -4%
QI
23
QS Investors
New York
$1.95M – – –
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$1.83M +$1.77M +184,138 New
Russell Investments Group
25
Russell Investments Group
United Kingdom
$1.7M +$225K +23,410 +16%
1
2 3 4 5

CNCE Hedge Fund Activity: Q2 2020 in Review

91 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2020, worth a combined $214M — up 22% from $175M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CNCE positions and 10 closed out — a net gain of 12 holders — while 32 added to existing stakes and 25 trimmed.

The largest buyer was SVB Wealth, opening a new position worth an estimated $3.66M. The largest seller was Sphera Funds Management, cutting an estimated $3M.

  • 91 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2020, up from 79 in Q1 2020.
  • Funds reported $214M of Concert Pharmaceuticals, Inc. stock for Q2 2020, up 22% quarter-over-quarter.
  • 22 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2020 and 10 closed out, a net change of +12 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q2 2020 was SVB Wealth, an estimated $3.66M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q2 2020 was Sphera Funds Management, an estimated $3M sold.

Based on aggregated 13F filings for Q2 2020.